Abstract
Psoriasis is a chronic, painful, disfiguring and non-contagious skin disease that has globally affected at least 200 million patients. In general, mild to moderate psoriasis patients will be treated by chemical drugs or Chinese medicine, while targeting systemic biological drugs have been successfully developed with good efficacy but high cost burden to patients with severe psoriasis. Since the underlying mechanisms of psoriasis are not well understood, in this review, psoriasis pathogenesis and clinical therapeutic principles by modern medicine and Chinese medicine are extensively described. Based on the data from the China Food and Drug Administration, the majority of chemical drugs are utilized as the topical formulations, while Chinese medicines are mainly delivered by an oral route, suggesting that the market for topical preparations of Chinese medicine to treat psoriasis is worth to exploration. Moreover, considering the unique clinical therapeutic theory and successful clinical application of Chinese medicine in the treatment of psoriasis, we believe that development of new small molecule drugs based on Chinese medicine will be a promising strategy to reduce therapeutic costs and improve safety for psoriatic patients.
Highlights
Psoriasis Psoriasis is a chronic, painful, disfiguring and non-infectious skin disease that is believed to be an autoimmune inflammation disorder with unclear underlying mechanism [1]
Stelara has even become the therapeutic standard for judging new psoriasis systemic biologic drugs, because after 28 weeks of treatment, the Psoriasis Area Severity Index (PASI) 75 standard ratio, which is the percentage of patients achieving a reduction of at least 75% in their baseline PASI at a given time, could reach approximately 80% [21, 22]
Because of the abnormal appearance and texture of the skin, it is likely that psoriasis patients will be less likely to take part in social activities because of depression, so apparent skin treatment is more important
Summary
Psoriasis Psoriasis is a chronic, painful, disfiguring and non-infectious skin disease that is believed to be an autoimmune inflammation disorder with unclear underlying mechanism [1]. Stelara has even become the therapeutic standard for judging new psoriasis systemic biologic drugs, because after 28 weeks of treatment, the PASI 75 standard ratio, which is the percentage of patients achieving a reduction of at least 75% in their baseline PASI at a given time, could reach approximately 80% [21, 22]. Mild to moderate psoriasis patients will usually use topical drugs, regulating gene transcription, to inhibit the proliferation of cells and boost the differentiation of keratinocytes.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
